Track topics on Twitter Track topics that are important to you
Shire said today its board has rejected at least two takeover proposals by Takeda Pharmaceutical, but both companies have confirmed that they remain in talks about a possible acquisition. Shire’s board turned down Takeda’s initial approximately £41 billion ($58.4 billion) takeover offer, which would have left Shire shareholders owning 50% of the combined company—and a third proposal in which Takeda raised its offer for Shire to approximately £44 billion ($62.6 billion), and would have given Shire shareholders about 51% of the Shire–Takeda combo. Not clear from Shire’s announcement is whether the board additionally rejected Takeda’s second takeover offer of approximately £43 billion ($61.2 billion). Also unclear is whether Takeda’s offers for Shire included Shire’s oncology business—which Shire said Monday it agreed to sell to Servier for $2.4 billion . Takeda has previously said that expanding its oncology business was a significant reason why it was considering ...
Original Article: Shire Rejects Takeda Takeover BidsNEXT ARTICLE
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...